1. Cytokines frequently implicated in myeloproliferative neoplasms. Issue 1 (March 2019) Authors: Wang, Yingying; Zuo, Xuelan Journal: Cytokine Issue: Volume 1:Issue 1(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Mad2 overexpression is associated with high cell proliferation and reduced disease-free survival in primary gastrointestinal diffuse large B-cell lymphoma. Issue 7 (8th August 2016) Authors: Chen, Fei; Liu, Shangqin; Zhou, Yi; Shen, Hui; Zuo, Xuelan Journal: Hematology Issue: Volume 21:Issue 7(2016) Page Start: 399 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial. Issue 7 (July 2022) Authors: Song, Yuqin; Liu, Yanyan; Li, Zhi-Ming; Li, Lanfang; Su, Hang; Jin, Zhengming; Zuo, Xuelan; Wu, Jianyuan; Zhou, Hui; Li, Kunyan; He, Chuan; Zhou, Jianfeng; Qi, Junyuan; Hao, Siguo; Cai, Zhen; Li, Yijing; Wang, Weiwei; Zhang, Xiaojing; Zou, Jianjun; Zhu, Jun Journal: Lancet Issue: Volume 9:Issue 7(2022) Page Start: e493 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗